For instance, healthcare workers are exposed to disinfectants and hand sanitizers, which break down the skin ... and improving skin barrier function. Approved only through the European Medicines ...

"Culture Quest explores the world of pop culture, history and thought-provoking ideas! We dive deep into the stories, concepts, and discoveries that shape our world. Follow us for engaging content ...

This cream made it to our list of Best Anti-Aging Hand Creams, and not one but two dermatologists endorse its healing effects. Dr. Debra Jaliman, a New York City-based, board-certified dermatologist, ...

Countertop sanitizers, on the other hand, are larger and are designed to sanitize multiple toothbrushes at once. We spent hours researching and testing various toothbrush sanitizers to identify ...

Uttarakhand has moved closer to implementing the Uniform Civil Code (UCC) as the state cabinet has approved the necessary rules for its rollout. This landmark decision aims to establish a unified ...

The FDA also gave its nod to Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride), the first new class of antischizophrenia drug to be approved in decades. Roughly one-third of last ...

However, it had to be used in conjunction with an oral medication. The FDA has now expanded its approval to include the standalone use of the nasal spray for adults with treatment-resistant major ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

J&J announced the FDA’s supplemental approval Tuesday. Previously, Spravato was approved as an add-on therapy for treatment-resistant depression, in conjunction with an oral antidepressant.